RESUMO
BACKGROUND: Qingchang Suppository, a formula used for more than 30 years in Longhua Hospital, has shown satisfactory clinical effects on Ulcerative Colitis (UC). However, its therapeutic mechanism has not been fully elucidated. PURPOSE: The study aims to investigate the effects of Qingchang Suppository powder (QCSP) and its ingredients by regulating the IL-17A signaling pathway which plays an important role in the development of UC. METHODS: HPLC was used to analyze the main ingredients (Gallic acid, Indigo, Indirubin) in QCSP. HT-29 cells were induced by rhIL-17A and TNF-α, and IL-17A related protein expressions were determined by western blot. BALB/C mice were induced by 4% Dextran Sodium sulfate (DSS). The effects of QCSP and its ingredients were evaluated by measuring weight loss, disease activity index (DAI), colon length, histological analysis. Western blot was used for analysis of IL-17A and MAPK related proteins p-ERK, p-JNK, p-P38. Quantitative reverse transcription polymerase chain reaction (q-PCR) was used to detect the expression of IL-17A, HSP90 and ACT1 in colon tissue. Cytokines such as IL-17A, IL-1ß, IFN-γ and TNF-α were determinated by enzyme-linked immunosorbent assay (ELISA). RESULTS: QCSP had good therapeutic effect on DSS-induced colitis in mice. QCSP significantly relieved weight loss, restored colon length, repaired colon lesions, reduced histological scores and DAI, decreased TNF-α, IL-1ß, IL-17 and IFN-γ contents, significantly suppressed the gene expressions of IL-17A, ACT1 and HSP90, and up-regulated the expressions of tight junction proteins like ZO-1 and Occludin. IL-17A pathway related proteins such as IL-17A, IL-17RA, HSP90, MAPKs, P-iκbα and iNOS were significantly increased in vitro and in vivo. CONCLUSIONS: This paper reveals that QCSP inhibited the IL-17A signaling pathway in HT-29 cells and DSS induced mice, presenting a new mechanism of QCS on treating UC.
Assuntos
Colite Ulcerativa/tratamento farmacológico , Sulfato de Dextrana/toxicidade , Interleucina-17/metabolismo , Animais , Colite Ulcerativa/induzido quimicamente , Citocinas/genética , Citocinas/metabolismo , Modelos Animais de Doenças , Medicamentos de Ervas Chinesas/toxicidade , Células HT29 , Humanos , Interleucina-17/genética , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Pós/efeitos adversos , Transdução de Sinais/efeitos dos fármacos , Supositórios/administração & dosagem , Supositórios/efeitos adversosAssuntos
Constipação Intestinal/terapia , Impacção Fecal/terapia , Oncologia/normas , Neoplasias/complicações , Adulto , Fatores Etários , Idoso , Envelhecimento/fisiologia , Analgésicos Opioides/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Dor do Câncer/tratamento farmacológico , Dor do Câncer/etiologia , Constipação Intestinal/diagnóstico , Constipação Intestinal/etiologia , Constipação Intestinal/psicologia , Enema/efeitos adversos , Enema/métodos , Enema/normas , Europa (Continente) , Impacção Fecal/diagnóstico , Impacção Fecal/etiologia , Impacção Fecal/psicologia , Motilidade Gastrointestinal/efeitos dos fármacos , Motilidade Gastrointestinal/fisiologia , Humanos , Laxantes/administração & dosagem , Laxantes/efeitos adversos , Massagem/métodos , Massagem/normas , Oncologia/métodos , Neoplasias/sangue , Neoplasias/terapia , Autocuidado/métodos , Autocuidado/normas , Sociedades Médicas/normas , Supositórios/administração & dosagem , Supositórios/efeitos adversos , Resultado do TratamentoAssuntos
Transtornos de Enxaqueca/tratamento farmacológico , Proctite/induzido quimicamente , Proctite/patologia , Supositórios/efeitos adversos , Acetaminofen/administração & dosagem , Acetaminofen/efeitos adversos , Adulto , Analgésicos não Narcóticos/administração & dosagem , Analgésicos não Narcóticos/efeitos adversos , Analgésicos Opioides/administração & dosagem , Analgésicos Opioides/efeitos adversos , Cafeína/administração & dosagem , Cafeína/efeitos adversos , Estimulantes do Sistema Nervoso Central/administração & dosagem , Estimulantes do Sistema Nervoso Central/efeitos adversos , Doença Crônica , Endoscopia do Sistema Digestório , Feminino , Humanos , Ópio/administração & dosagem , Ópio/efeitos adversos , Úlcera/induzido quimicamente , Úlcera/patologiaRESUMO
We assessed the acceptability of three of over-the-counter products representative of potential rectal microbicide (RM) delivery systems. From 2009 to 2010, 117 HIV-uninfected males (79 %) and females (21 %) who engage in receptive anal intercourse participated in a 6-week randomized crossover acceptability trial. Participants received each of three products (enema, lubricant-filled applicator, suppository) every 2 weeks in a randomized sequence. CASI and T-ACASI scales assessed product acceptability via Likert responses. Factor analysis was used to identify underlying factors measured by each scale. Random effects models were fit to examine age and gender effects on product acceptability. Three underlying factors were identified: Satisfaction with Product Use, Sexual Pleasure, and Ease of Product Use. For acceptability, the applicator ranked highest; however, differences between product acceptability scores were greatest among females and younger participants. These findings indicate that RM delivery systems impact their acceptability and should be considered early in RM development to enhance potential use.
Assuntos
Anti-Infecciosos Locais/administração & dosagem , Anti-Infecciosos Locais/efeitos adversos , Sistemas de Liberação de Medicamentos/métodos , Infecções por HIV/prevenção & controle , Aceitação pelo Paciente de Cuidados de Saúde/psicologia , Reto/efeitos dos fármacos , Administração Retal , Adulto , Estudos Cross-Over , Sistemas de Liberação de Medicamentos/instrumentação , Enema/estatística & dados numéricos , Feminino , Humanos , Lubrificantes/administração & dosagem , Lubrificantes/efeitos adversos , Masculino , Pessoa de Meia-Idade , Reto/química , Comportamento Sexual , Supositórios/administração & dosagem , Supositórios/efeitos adversos , Resultado do TratamentoRESUMO
Medications that are given via the rectal route are prescribed for a variety of reasons and have either a local or systemic effect. The administration of suppositories and enemas is an intimate procedure which has the potential to cause embarrassment and discomfort for the patient. This article outlines the reasons for the use of rectal medications and recommends a procedure to be followed when giving them.
Assuntos
Enema/efeitos adversos , Supositórios/efeitos adversos , Adulto , Vias de Administração de Medicamentos , HumanosRESUMO
After having done a wide study in vitro and in vivo reported in several publications, we applied the lyophylized extract "Pelnicol" under the form of suppositories, in 36 cases of secondary back diseases. The improvement with "Pelnicol" suppositories is observed, by mean, the 6th day of treatment. It can be seen that etiopathological factors are determining the diseases evolution, which has to be, in first rang, considered causally. It is realised with the "Pelnicol" suppositories.